PRTN3 and androgen insensitivity syndrome: Higher plasma PR3 levels are also found significantly associated with AIS patients with unfavorable functional outcomes and 3-month mortality and contribute to the efficiency of the prediction model in our study, which to some extent explains the possible role of PR3 preliminarily outlined in the preclinical study [13].